Grand opening of the first China Pharmaceutical Innovation and Investment Conference

Source: on the morning of November 14, 2016, the first China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as "the conference") was held in Suzhou JinJiHu International Conference Center The conference is jointly sponsored by China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China pharmaceutical promotion association") and China Securities Association, "major new drug creation" The implementation and Management Office of major science and technology projects, the Research Center for medical and health science and technology development of the national health and Family Planning Commission, the science and technology promotion and Development Bureau of the Chinese Academy of Sciences, the Chinese Academy of Medical Sciences, the Chinese Academy of traditional Chinese medicine, the Chinese Academy of Military Medical Sciences of the people's Liberation Army, the experts Association of the 1000 person plan of the central organization, and Suzhou Industrial Park are the supporting units The inter agency quotation system of the Chinese Academy of Sciences has Ltd., Baihua Association, tongsketchi new medicine talent club and Shanghai dongfulong Technology Co., Ltd jointly organized The conference also won the participation and support of JP Morgan group, a famous international investment bank As the first professional media and exclusive network media, nature and people's network, the world's top professional magazines, together with China Securities News, health news, pharmaceutical economic news, China Pharmaceutical News and other professional media, are the media support units of the conference, covering the whole process of the conference At the same time, representatives from the embassies and consulates of the United States, Canada, France, Israel and other countries in China, CBBC, JPMA, MRCT and other pharmaceutical related industries were invited to attend the conference Opening ceremony of the conference Song Ruilin, executive chairman of the Organizing Committee of the conference and executive chairman of the China Association for the promotion of medicine, presided over the speech stage of the leaders of the opening ceremony, and introduced the background, preparations and guests of the conference Wang Xiang, member of the Standing Committee of the CPC Suzhou Municipal Committee, vice mayor and Secretary of the working committee of the Suzhou Industrial Park, on behalf of the Suzhou Industrial Park, warmly welcomed all the guests, expecting experts from the pharmaceutical and investment circles at home and abroad to attend the conference The conference will be able to spark cooperation and inject new vitality and impetus into Suzhou's transformation and development Chairman of the Organizing Committee of the conference, China Council for the promotion of drugs 2016-2017 Ding liming, the annual president and chairman of Beida pharmaceutical industry, introduced the achievements made by China pharmaceutical innovation promotion association in promoting the improvement of policy environment in the whole chain of pharmaceutical innovation He hoped to unite more industry leading representatives committed to innovation and R & D in the pharmaceutical industry, and help China Pharmaceutical Promotion Association to jointly promote the innovation and sustainable development of China's pharmaceutical industry Chen Gongyan, chairman of the Organizing Committee of the conference and President of China Securities Association, pointed out that it is necessary to accurately grasp the national strategic guidance for innovation driven and healthy China Construction, and on the basis of highly recognizing the importance of investment and innovation, made a prospect and plan for China Securities Association to promote the integration of innovation and investment in the future Song Ruilin, executive chairman of the Organizing Committee and China Association for the promotion of drugs, presided over the opening ceremony Ding liming, chairman of the organizing committee, 2016-2017 president of China Association for the promotion of drugs and chairman of Beida pharmaceutical, delivered a speech Then, the conference focused on "promoting the combination of social capital and innovation, and improving the innovation ability of pharmaceutical industry" This paper focuses on and discusses the policy environment and development trend of new drug R & D in China, and how to combine pharmaceutical innovation with investment The first phase of the conference is "national drug policy thematic report" Sun Xianze, deputy director of the State Food and drug administration, Zhou Siyuan, deputy director of the drug review center of the State Food and drug administration, Chen Kaixian, deputy chief engineer of major special technology for new drugs and chairman of Shanghai Association of science and technology, respectively, focused on the reform and progress of the national drug review and approval system, and the national "major new drug creation" Report on the implementation performance of major science and technology projects and the current situation of pharmaceutical innovation and development in China Under the theme of "reform of drug review and approval system", sun Xianze introduced the path design and reform direction of the reform of national drug review and approval system in recent two years Through strict examination and approval of new drugs on the market, China's drug level and international competitiveness will be improved, so that China's "new" will become the global "new" To carry out the pilot of listing holder system in ten provinces and cities to encourage scientific and technological innovation and ensure the supply of drugs; to carry out the consistency evaluation of generic drugs to ensure that the drugs can be replaced by the original drugs in clinical practice through consistency evaluation; to carry out the data verification of clinical trials to rebuild the environment of drug research occurrence; to clear the policy of solving the backlog of evaluation, to encourage innovation as the guide, and to combine the standard with the fundamental, Accelerate the establishment of a scientific and efficient review and approval system Sun Xianze, deputy director of the State Food and drug administration, Zhou Siyuan, deputy director of CFDA, introduced in detail the recent CFDA drug review center in terms of solving the backlog of registration applications, technical review reform, construction of technical review team, and improving the efficiency of drug review with the theme of "progress in drug technical review and reform" In order to solve the backlog of registration applications, CDE has carried out a series of reforms, and it is expected that new applications and supplementary applications for chemical, Chinese and biological drugs will be reviewed normally in 2017; the reform of technical review will continue to be carried out in accordance with GF [2015] 44 In accordance with the requirements of the opinions of the State Council on the reform of the review and approval system for pharmaceutical and medical devices, and in accordance with the laws of drug research and development and the regulatory norms for innovative drugs, we have gradually achieved scientific supervision Simplify the approval process of clinical application, strengthen the communication and exchange before clinical application, change the concept and adjust the review ideas, focus on the scientific and safety risk control of clinical trial scheme, ensure the safety of the subjects; follow the procedures of guidance before, communication during, and review decision after, and improve the standard guidance mechanism of drug review; each specialty has been formulated in the early stage On the basis of more than 120 technical guidelines in the industry, accelerate the construction of chemical, Chinese and biological drug evaluation standards and guidance systems; properly resolve technical disputes through review of technical disputes, establishment of expert committees, etc.; open review information, explore file review, review organization and management team construction, etc In terms of the construction of technical evaluation team, the next key work is to strengthen personnel training, strict personnel management, adjust the internal organization and rationalize the management mechanism; at the same time, increase the recruitment and enrich the employment mechanism Academician Zhou Siyuan and Chen Kaixian, deputy director of the drug evaluation center of the State Food and drug administration, focused on the theme of "overview of the current situation of innovation and development of China's pharmaceutical industry", made achievements in the current economic operation of the pharmaceutical industry, the implementation of major science and technology projects of "major new drug creation" and "major new drug creation" The overall performance evaluation of major science and technology projects is systematically described, and the development prospect and investment direction of pharmaceutical industry innovation are prospected by analyzing a number of policies that encourage innovation in the near future After the opening ceremony of academician Chen Kaixian, deputy chief engineer of national major new drug special technology and chairman of Shanghai Association of science and technology, all the guests witnessed the signing ceremony of the cooperation agreement on "medical innovation platform" jointly established by Suzhou Municipal People's government, China Securities Association, China pharmaceutical innovation promotion association and Suzhou Industrial Park Management Committee Song Ruilin, executive chairman of the Organizing Committee and the China Association for the promotion of drugs, presided over the signing ceremony After full and friendly consultation, the above four parties decided to set up a pharmaceutical innovation platform in Suzhou Industrial Park They will discuss Suzhou Industrial Park as a regular venue of "China Pharmaceutical Innovation and investment conference", establish a pharmaceutical industry innovation and research base, strengthen policy research and training, establish a coordination mechanism, and explore the establishment of in-depth cooperation in innovation and investment The second innovation investment conference will continue to be held in Suzhou Industrial Park, tentatively scheduled for October 29-31, 2017 Welcome to meet next year The second stage of the signing ceremony conference "theme report on the development and investment of the pharmaceutical industry" was presided over by Jiang Hualiang, chairman of the Organizing Committee of the conference, 2015-2016 president of China pharmaceutical promotion association and director of Shanghai Institute of pharmaceutical research Jiang Hualiang, chairman of the organizing committee, 2015-2016 president of China pharmaceutical promotion association and director of Shanghai Pharmaceutical Research Institute, presided over the second stage report of the conference jp.s.ross, managing director of JP Morgan medical and health investment banking department, with "development trend and relevant analysis of biopharmaceutical market" For the theme of the development of the international biopharmaceutical market, this paper makes a wonderful analysis with detailed data and gives reasonable investment suggestions; Dr Gao Shanwen, chief economist of Anxin securities, pays attention to the "progress and Prospect of supply side reform" in the employment field, introduces the adjustment and progress of the industrial structure of supply side reform of traditional Chinese medicine and provides a good reference for the development of pharmaceutical enterprises Finally, Dr Gao Shanwen, chief economist of Anxin securities, Mr Philip S Ross, managing director of JP Morgan medical health investment banking department Finally, "dialogue between pharmaceutical innovation scientists, entrepreneurs and investment experts" is presided over by song Ruilin, executive chairman of the Organizing Committee of the conference and executive chairman of China Pharmaceutical Promotion Association Chen Kaixian, deputy chief engineer of major science and technology special project of "major new drug creation", chairman of Shanghai Association of science and technology, Chen Jianfeng, Dean of School of chemical engineering, Beijing University of chemical technology and academician of Chinese Academy of engineering, China Council for the promotion of drugs 2014-2015 Sun piaoyang, the annual president and chairman of Jiangsu Hengrui Pharmaceutical Co., Ltd., as the representative of the pharmaceutical innovation community, Du Ying, the chairman of the Organizing Committee of the conference and the chairman of the pharmaceutical innovation investment special committee of China pharmaceutical promotion association, Li Kaijun, the vice chairman of the pharmaceutical innovation investment Special Committee of China pharmaceutical promotion association, and Qiang Jing, the executive general manager of the research department of China International Finance Co., Ltd., as the representative of the investment community Dialogue and exchange have been held with regard to the docking of pharmaceutical innovation and investment The excellent agenda and rich contents of the opening ceremony of the panel conference of dialogue between medical innovation scientists, entrepreneurs and investment experts have attracted great attention of representatives from all walks of life in the pharmaceutical industry at home and abroad From the on-site registration, more than 650 institutions, including domestic and foreign investment institutions, pharmaceutical innovation enterprises, medical and pharmaceutical research units and law firms, registered and attended the conference, with more than 1200 Several representatives attended the opening ceremony, which was unprecedented in scale The opening ceremony of the conference was held successfully to enhance the industry's understanding of the trend of national drug regulatory policies, deepen the investment community's understanding of pharmaceutical innovation, and build a good platform; it was also the global launch of clinical data of several first drugs in the afternoon, and the special roadshow of innovative enterprises, projects and gene sequencing and diagnostic reagents on the 15th and 16th, "pharmaceutical innovation and investment trend analysis" ”The smooth progress of the policy forum has opened a good prelude The rich agenda of the opening ceremony was highly affirmed and warmly responded by the participants It is believed that the following activities of the conference will provide a professional and comprehensive platform for representatives from all walks of life of pharmaceutical investment to further understand the latest progress of innovation in sub industries in the pharmaceutical field Please look forward to the report on the follow-up activities of the conference!